Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eurofarma's Pegfilgrastim vs Neulastim in Breast Cancer
NCT02768714Phase 3Withdrawn
- Sponsor
- Eurofarma
- Start
- Jan 2018
- Primary completion
- Oct 2019
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, single-blind trial of pegfilgrastim in neutropenia (2 arms), sponsored by Eurofarma. Primary endpoint: Duration of severe neutropenia (grade 4) in days during chemotherapy cycle 1. Planned start Jan 2018; status: withdrawn.
02
Drugs
pegfilgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT02768714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02768714.